Shorts are trapped, page-14

Let's hear it, because last I checked these guys have done a pretty good job of turning this company into one of the very few biotechs that actually makes cash consistently rather than burn it and raise it. The price has gone down with the broader healthcare sector, but at least they haven't diluted us so much along the way as to make it impossible to return to the highs (and much higher above those highs). Again, if you want a company that will raise half its market cap in cash and go all out on chasing approvals that often don't end well, there's a large basket to pick from. Not sure why you'd be investing in CUV? I really like the approach, ie not moving ahead with Vitiligo until they had sufficient proof to be confident in approval and sufficient reimbursement, but I could imagine how it might be frustrating for someone with a limited level of patience